Breakthroughs and challenges in the management of pediatric viral hepatitis

Table 1 Pediatric studies of different combinations of direct-acting antivirals

Drug regimen	Age range in yr	Sample size	Genotype(s)	Number of patients with SVR12, %	Ref.
Sofosbuvir/ledipasvir	12-17	100	1	98/100 (98)	Balistreri et al[25]
	6-11	92	1, 3, 4	91/92 (99)	Murray et al[26]
	3-5	34	1, 4	33/34 (97)	Schwarz et al[27]
Sofosbuvir plus ribavirin	12-17	52	2, 3	51/52 (98)	Wirth et al[33]
	6-11	41		41/41 (100)	Rosenthal et al[34]
	3-5	13		12/13 (92)	Rosenthal et al[34]
Sofosbuvir/velpatasvir	12-17	102	1, 2, 3, 4	97/102 (95)	Sokal et al[35]
	6-11	73		68/73 (93)	Sokal et al[35]
	3-5	41		34/41 (83)	Sokal et al[35]
Glecaprevir/pibrentasvir	12-17	47	1, 2, 3, 4	47/47 (100)	Jonas et al[36]
	6-11	32		31/32 (97)	Jonas et al[37]
	3-5	16		15/16 (96)	Jonas et al[37]
Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin	12-17	38	1, 4	38/38 (100)	Leung et al[134]
	6-11	26	1	25/26 (95)	Rosenthal et al[135]
Elbasvir/grazoprevir	12-17	22	1, 4	22/22 (100)	Wirth et al[136]
	6-11	17		17/17 (100)	Wirth et al[136]
	3-5	18		18/18 (100)	Wirth et al[136]
Sofosbuvir/velpatasvir/voxilaprevir	12-17	21	1, 2, 3, 4	21/21 (100)	Bansal et al[137]
Sofosbuvir plus daclatasvir	15-17	13	4	13/13 (100)	El-Sayed et al[138]
	13-17	10		10/10 (100)	El-Shabrawi et al[139]
	12-17	30		29/29 (100)	Yakoot et al[140]
	8-17	40	1, 4	39/39 (100)	Abdel Ghaffar et al[141]
	7-13	14	3	14/14 (100)	Padhi et al[57]

SVR12: Sustained virological response 12 wk after the end of treatment.